Search results for "breast disease"

showing 10 items of 40 documents

EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer

2012

Background In early estrogen receptor (ER)-positive/HER2-negative breast cancer, the decision to administer chemotherapy is largely based on prognostic criteria. The combined molecular/clinical EndoPredict test (EPclin) has been validated to accurately assess prognosis in this population. In this study, the clinical relevance of EPclin in relation to well-established clinical guidelines is assessed. Patients and methods We assigned risk groups to 1702 ER-positive/HER2-negative postmenopausal women from two large phase III trials treated only with endocrine therapy. Prognosis was assigned according to National Comprehensive Cancer Center Network-, German S3-, St Gallen guidelines and the EPc…

Oncologymedicine.medical_specialtyEndoPredict geneAntineoplastic Agents HormonalReceptor ErbB-2Populationadjuvant treatmentBreast NeoplasmsKaplan-Meier EstimateAnastrozoleRisk AssessmentDisease-Free SurvivalBreast cancerInternal medicineBreast CancerexpressionAntineoplastic Combined Chemotherapy ProtocolsNitrilesmedicineHumanseducationSurvival analysisRetrospective Studieseducation.field_of_studybusiness.industryendocrine therapyAbsolute risk reductionRetrospective cohort studyHematologyOriginal ArticlesMiddle AgedTriazolesmedicine.diseasePrognosisChemotherapy regimenSurgeryTamoxifenTreatment OutcomeOncologyReceptors EstrogenChemotherapy AdjuvantPractice Guidelines as TopicFemaleBreast diseasebusinessRisk assessmentAnnals of Oncology
researchProduct

Validity of needle core biopsy in the histological characterisation of mammary lesions

2006

Summary Over the last few years, there has been an enormous increase in the use of needle core biopsy (CB) for the histopathological characterisation of suspect lesions of the breast. The aim of this study was to verify the diagnostic reliability of CB by comparing the histological results obtained with the use of this technique with those obtained from the whole of the surgically resected specimen. We studied 198 out of 426 patients with clinically and/or radiologically suspect breast lesions. We found correspondence between the histological examination of the whole of the excised specimen and that of the CB in 94.9% of the cases of infiltrating carcinoma and in 71.4% of those involving du…

Pathologymedicine.medical_specialtyReproducibility of ResultBreast NeoplasmsSensitivity and SpecificityBreast cancerNeedle core biopsyRetrospective StudiemedicineCarcinomaHumansbreast carcinomahumanintermethod comparisonarticle; breast carcinoma; breast disease; carcinoma in situ; diagnostic accuracy; diagnostic value; histopathology; human; human tissue; intermethod comparison; intraductal carcinoma; major clinical study; needle biopsy; prediction; priority journal; reliability; sensitivity and specificity; validation process Biopsy Needle; Breast Neoplasms; Carcinoma Ductal Breast; Carcinoma Intraductal Noninfiltrating; Female; Humans; Reproducibility of Results; Retrospective Studies; Sensitivity and Specificity [EMTREE medical terms]Retrospective Studiesintraductal carcinomaHistological examinationreliabilitybusiness.industryBiopsy Needlevalidation process MeSH: Biopsy NeedleCarcinoma Ductal Breastbreast diseaseReproducibility of Resultscarcinoma in situneedle biopsypredictionGeneral Medicinemedicine.diseasemajor clinical studyPredictive valuehuman tissueCarcinoma Intraductal Noninfiltratingpriority journalhistopathologyEMTREE medical terms: articlediagnostic accuracyFemaleSurgerydiagnostic valueRadiologybusinessCore biopsyBreast NeoplasmThe Breast
researchProduct

Gas chromatography/mass spectrometry of catechol estrogens

1992

Abstract Catecholestrogens (CCEs), namely 2- or 4-hydroxyestradiol and hydroxyestrone, are highly polar, reactive, and extremely labile estrogen metabolites in many experimental conditions. For these reasons, indirect assay methods mainly have been used. Some experimental evidence suggests that CCEs are synthesized and biologically active mostly in target cells. At this level, unfortunately, the indirect assays cannot be used. We present a method of gas Chromatographic/mass spectral (GC/MS) analysis for the identification of individual CCEs; the major fragmentation ions of authentic estrogen standards as trimethylsilylether derivatives, and the MS patterns of the major CCEs, namely, 2-hydro…

PharmacologyDetection limitCatecholChromatographyElutionOrganic ChemistryClinical BiochemistryPolyatomic ionBreast NeoplasmsBiological activityMass spectrometryBiochemistryEstrogens CatecholGas Chromatography-Mass Spectrometrychemistry.chemical_compoundEndocrinologychemistryHumansFemaleGas chromatographyGas chromatography–mass spectrometryFibrocystic Breast DiseaseMolecular BiologyChromatography High Pressure LiquidSteroids
researchProduct

Integrative analysis of cyclin protein levels identifies cyclin b1 as a classifier and predictor of outcomes in breast cancer

2009

Abstract Purpose: We studied the expression levels of cyclins B1, D1, and E1 and the implications of cyclin overexpression for patient outcomes in distinct breast cancer subtypes defined by clinical variables and transcriptional profiling. Experimental Design: The expression levels of cyclins B1, D1, and E1 were quantified in 779 breast tumors and 53 cell lines using reverse phase protein arrays and/or transcriptional profiling. Results: Whereas cyclin E1 overexpression was a specific marker of triple-negative and basal-like tumors, cyclin B1 overexpression occurred in poor prognosis hormone receptor–positive, luminal B and basal-like breast cancers. Cyclin D1 overexpression occurred in lum…

ProteomicsCancer ResearchPathologymedicine.medical_specialtyCyclin EClass I Phosphatidylinositol 3-KinasesCyclin DDNA Mutational AnalysisCyclin BBreast NeoplasmsBiologyCyclin BArticlePhosphatidylinositol 3-KinasesCyclin D1Predictive Value of TestsCell Line TumorCyclin Emedicine1-Phosphatidylinositol 3-KinaseHumansCyclin D1BreastCyclin B1Cyclin B1Oligonucleotide Array Sequence AnalysisProportional Hazards ModelsOncogene ProteinsGene Expression ProfilingCancermedicine.diseasePrognosisImmunohistochemistrySurvival AnalysisGene Expression Regulation NeoplasticCyclin E1OncologyReceptors EstrogenSpectrometry Mass Matrix-Assisted Laser Desorption-IonizationMutationCancer researchbiology.proteinFemaleBreast diseaseReceptors Progesterone
researchProduct

Endothelial cells and normal breast epithelial cells enhance invasion of breast carcinoma cells by CXCR-4-dependent up-regulation of urokinase-type p…

2008

Here we show the increase of invasion of three breast cancer cell lines (8701-BC, MDA-MB-231 and SKBR3) upon long-term co-incubation with culture medium of normal microvascular endothelial cells (MVEC) and normal breast epithelial cells (HB2). The enhancement of invasion relied on the interaction of microvascular endothelial cell and normal breast epithelial cell CXCL12 (SDF1) chemokine, whose expression by breast cancer cells was very low, with the cognate CXCR4 receptor of malignant cells, which resulted in over-expression of the urokinase-type plasminogen activator receptor (uPAR) on their surfaces. uPAR over-expression, showed by RT-PCR and Western blotting, was paralleled by increased …

Receptors CXCR4MAP Kinase Kinase 4AngiogenesisCellBreast NeoplasmsReceptors Cell SurfaceCell CommunicationBiologyCell LineReceptors Urokinase Plasminogen ActivatorPathology and Forensic MedicineMetastasisangiogenesisbreast cancerTumor Cells CulturedmedicineHumansNeoplasm InvasivenessBreastSettore BIO/06 - Anatomia Comparata E CitologiaPhosphorylationskin and connective tissue diseasesCXCR4Settore MED/04 - Patologia GeneraleNeovascularization PathologicReverse Transcriptase Polymerase Chain ReactionFibrinolysisEpithelial CellsCXCL12invasionmedicine.diseasemicroenvironmentChemokine CXCL12Neoplasm ProteinsUp-RegulationEndothelial stem cellUrokinase receptormedicine.anatomical_structureCulture Media ConditionedCancer cellCancer researchFemaleJNKEndothelium VascularBreast diseaseSDF1uPARPlasminogen activatorThe Journal of Pathology
researchProduct

Characterization of a Naturally Occurring Breast Cancer Subset Enriched in Epithelial-to-Mesenchymal Transition and Stem Cell Characteristics

2009

Abstract Metaplastic breast cancers (MBC) are aggressive, chemoresistant tumors characterized by lineage plasticity. To advance understanding of their pathogenesis and relatedness to other breast cancer subtypes, 28 MBCs were compared with common breast cancers using comparative genomic hybridization, transcriptional profiling, and reverse-phase protein arrays and by sequencing for common breast cancer mutations. MBCs showed unique DNA copy number aberrations compared with common breast cancers. PIK3CA mutations were detected in 9 of 19 MBCs (47.4%) versus 80 of 232 hormone receptor–positive cancers (34.5%; P = 0.32), 17 of 75 HER-2–positive samples (22.7%; P = 0.04), 20 of 240 basal-like c…

Receptors SteroidCancer ResearchPathologymedicine.medical_specialtyTranscription GeneticClass I Phosphatidylinositol 3-KinasesBreast NeoplasmsArticleCohort StudiesProto-Oncogene Proteins p21(ras)Phosphatidylinositol 3-KinasesBreast cancerProto-Oncogene ProteinsBiomarkers TumormedicineHumansRNA NeoplasmEpithelial–mesenchymal transitionskin and connective tissue diseasesComparative Genomic HybridizationMetaplasiabiologyGene Expression ProfilingCD44PTEN PhosphohydrolaseCancerEpithelial CellsMesenchymal Stem CellsSarcomaDNA NeoplasmMetaplastic Breast Carcinomamedicine.diseaseClaudin-LowOncologyMutationCarcinoma Squamous Cellras Proteinsbiology.proteinCancer researchFemaleBreast diseaseStem cellProto-Oncogene Proteins c-aktCancer Research
researchProduct

In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients.

2010

The potent anti-tumour activities of gamma delta T cells have prompted the development of protocols in which gamma delta-agonists are administered to cancer patients. Encouraging results from small Phase I trials have fuelled efforts to characterize more clearly the application of this approach to unmet clinical needs such as metastatic carcinoma. To examine this approach in breast cancer, a Phase I trial was conducted in which zoledronate, a V gamma 9V delta 2 T cell agonist, plus low-dose interleukin (IL)-2 were administered to 10 therapeutically terminal, advanced metastatic breast cancer patients. Treatment was well tolerated and promoted the effector maturation of V gamma 9V delta 2 T …

Translational Studiesmedicine.medical_treatmentLymphocyte ActivationZoledronic AcidMetastasisTNF-Related Apoptosis-Inducing LigandProstate cancerT-Lymphocyte SubsetsImmunology and AllergyMedicineDiphosphonatesRemission InductionEsterasesImidazolesReceptors Antigen T-Cell gamma-deltaMiddle AgedMetastatic breast cancerTreatment Outcomemedicine.anatomical_structureDisease ProgressionCytokinesFemaleImmunotherapyBreast diseaseChemokinesT cellImmunologyBreast NeoplasmsInterferon-gammaHemiterpenesOrganophosphorus CompoundsBreast cancerAdjuvants ImmunologicVgamma9Vdelta2 T cells Zoledronate interleukin-2advanced breast cancer patientsHumansLymphocyte CountAgedCell ProliferationSalvage Therapybusiness.industryLysineMucin-1CancerImmunotherapymedicine.diseaseTumor Necrosis Factor Receptor Superfamily Member 7ImmunologyInterleukin-2Leukocyte Common Antigensbusiness
researchProduct

Standard treatment of female patients with breast cancer decreases substantially for women aged 70 years and older: a German clinical cohort study

2010

Standard treatment of patients with breast cancer decreases with age and older persons are mostly excluded from clinical trials. We hypothesized that non-adherence to treatment guidelines occurs for women agedor =70 years and changes overall survival (OAS) and disease-free survival (DFS).We enrolled 1922 women agedor =50 years with histologically confirmed invasive breast cancer treated at the University of Ulm from 1992 to 2005. Adherence to guidelines and effects on OAS and DFS for women agedor =70 years was compared with that for younger women (50-69 years).Women70 years less often received recommended breast-conserving therapy (70-79 years: 74%-83%;79 years: 54%) than women agedor =69 y…

medicine.medical_specialtyBreast NeoplasmsMedical OncologyCohort StudiesBreast cancerGermanyInternal medicinemedicineHumansMastectomySurvival analysisAgedAged 80 and overGynecologyRadiotherapybusiness.industryStandard treatmentCarcinomaHazard ratioAge FactorsCancerProfessional PracticeHematologyMiddle Agedmedicine.diseaseSurvival AnalysisChemotherapy regimenOncologyChemotherapy AdjuvantFemaleGuideline AdherenceBreast diseasebusinessCohort studyAnnals of Oncology
researchProduct

Steroid Patterns of Benign Breast Disease

1990

We briefly review some biochemical aspects of benign breast disease (BBD), mainly focusing on free and conjugate estrogen content of breast cyst fluid (BCF), also in relation to cyst type. Evidence is reported that high K(+)-type I-cysts clearly associate with low Cl- levels and accumulate significantly higher quantities of dehydroepiandrosterone sulfate (DHAS) and estrone-3-sulfate (E1S). In spite of the limited number of cases, both increasing DHAS and E1S levels correlate with the increment of K+ to Na+ ratio. A positive correlation was also found between DHAS and E1S. Using electrochemical detection (ECD) on-line to high performance liquid chromatography (HPLC) in the reverse phase mode…

medicine.medical_specialtyEstronemedicine.drug_classmedicine.medical_treatmentBreast NeoplasmsEstroneGeneral Biochemistry Genetics and Molecular BiologySteroidchemistry.chemical_compoundDehydroepiandrosterone sulfateBreast cancerHistory and Philosophy of ScienceInternal medicinemedicineHumansCystFibrocystic Breast DiseaseChromatography High Pressure LiquidDehydroepiandrosterone SulfateGeneral NeuroscienceSulfataseEstrogensDehydroepiandrosteroneMiddle Agedmedicine.diseaseEndocrinologychemistryEstrogenFemaleBreast diseaseAdenofibromaAnnals of the New York Academy of Sciences
researchProduct

A multicenter cohort study to compare quality of life in breast cancer patients according to sentinel lymph node biopsy or axillary lymph node dissec…

2009

Background: This prospective multicenter study assessed and compared the impact of different surgical procedures on quality of life (QoL) in breast cancer patients. Patients and methods: The EORTC QLQ-C30 and the EORTC QLQ-BR-23 questionnaires were used to assess global health status (GHS), arm (BRAS) and breast (BRBS) symptom scales, before surgery, just after surgery and 6 and 12 months later. The Kruskal–Wallis test with the Bonferroni correction was used to compare scores. A mixed model analysis of variance for repeated measurements was then applied to assess the longitudinal effect of surgical modalities on QoL. Results: Before surgery, GHS (P = 0.7807) and BRAS (P = 0.7688) QoL scores…

medicine.medical_specialtymedicine.medical_treatmentSentinel lymph nodeBreast NeoplasmsCohort StudiesBreast cancerQuality of lifemedicineHumansProspective Studiesbusiness.industrySentinel Lymph Node BiopsyAxillary Lymph Node DissectionHematologySentinel nodeMiddle Agedmedicine.diseasehumanitiesSurgeryOncologyLymphatic MetastasisQuality of LifeLymph Node ExcisionLymphadenectomyFemaleBreast diseaseLymph NodesbusinessCohort studyAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct